THERAMEX
A new international survey of 1,008 women with osteoporosis from six countries, launched on World Osteoporosis Day, reveals that while more than two-thirds (67%) of women over the age of 55 mostly understand what osteoporosis is and the potential negative impact of future fractures, 19% felt poorly informed at the time of the diagnosis.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005894/en/
The survey initiated by Theramex in cooperation with the International Osteoporosis Foundation (IOF), was conducted in Germany, France, Italy, Spain, Australia, and Brazil. It included 316 postmenopausal women over the age of 55 years and 315 premenopausal women (40-55 years) with osteoporosis (altogether 62% of the surveyed women). Of these women, osteoporosis was only diagnosed after a fracture in almost 60% of the cases. This survey highlights a gap in osteoporosis awareness, as one-fourth of the patients aged 55 years and over were not aware and did not understand the link between osteoporosis and bone fractures.1 A third (35%) of respondents said they would have been motivated to watch out for their bone health if they had known that one in three women aged over 50 will suffer a fragility fracture, but fragility fractures are preventable with the right treatment.1,2 In addition, close to 25% of postmenopausal women felt not listened to by their doctors when discussing their treatment.1
Osteoporosis is a chronic condition causing loss of bone mass and strength, resulting in fragile bones.3 It is a growing problem,3 affecting around 500 million people globally.4 Osteoporosis affects more women than men, with the risk increasing with age.5 Women are at higher risk of osteoporosis after the menopause, when the ovaries stop producing oestrogen, a hormone which has a protective effect on bones.5
Dr. Philippe Halbout, International Osteoporosis Foundation CEO said, “The impact of osteoporosis should not be underestimated. Fractures can be life-altering, causing pain, disability and loss of independence which is why it’s so important to ensure that patients are receiving the information, care and treatment they need to manage their condition and prevent or delay fractures. This survey highlights the need for improved doctor-patient communications and demonstrates the importance of education to empower women to ask for more from their care.”
Theramex CEO, Robert Stewart, commented, “Women with osteoporosis deserve support and appropriate treatment to help them continue to enjoy their lifestyles and precious moments with loved ones. We are committed to working with the osteoporosis community to provide accessible information and education about the condition, as the more women know and understand, the more they will be empowered to ask for more from their osteoporosis care, helping to reduce or eliminate the risk of fractures.”
This World Osteoporosis Day, women are being urged to #askformore from their osteoporosis care and treatment. For further information and osteoporosis resources, visit www.worldosteoporosisday.org
ENDS
NOTES TO EDITOR:
About the survey1
The online survey was conducted among 1,008 women with osteoporosis across six countries: Germany (73), France (74), Spain (122), Italy (298), Australia (54) and Brazil (387). The respondents were all female with 377 under 40, 315 aged 40-54, 201 aged 55-64, 90 aged 65-75 and 25 over 75. It should be noted that the risk of osteoporosis increases with age, despite the number of women in the younger age category in this survey. The survey was conducted between 5 – 12 July 2021 by Opinion Matters on behalf of Theramex.
About Osteoporosis
Osteoporosis remains largely underdiagnosed and undertreated, resulting in a large number of fractures.
- It is a significant health issue – affecting ~500 million people worldwide4
- Osteoporosis affects more women than men and risk increase with age5
- After the menopause women start to lose bone at a faster rate, raising the risk for women who have had an early menopause or hysterectomy5
- One in three women aged over 50 will suffer a fragility fracture2
- Hip, spine, and wrist fractures are the most common fractures in osteoporosis and have a debilitating impact on daily activities and quality of life2
- After a spine fracture, mortality is increased immediately after the fracture event6
- Spine fractures can lead to back pain, loss of height, deformity, immobility, impaired quality of life (QoL), and difficulties in activities of daily living7,8,9
About the International Osteoporosis Foundation (IOF)
The International Osteoporosis Foundation is the world’s largest non-governmental organization dedicated to the prevention, diagnosis, and treatment of osteoporosis and related musculoskeletal diseases.
IOF Vision
Our vision is a world without fragility fractures, in which healthy mobility is a reality for all.
IOF Mission
To promote bone and musculoskeletal health as a worldwide priority.
About Theramex
Theramex is a leading, global speciality pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives.
References:
- Opinion Matters. (2021) #Askformore Osteoporosis International Survey.
- Cooper, C. (2019) IOF Compendium of Osteoporosis . IOF. 2nd edition.
- Noh, J.Y., Yang, Y. & Jung, H. (2020) Int J Mol Sci. 21 (20), 7623
- IOF. (n.d.) IOF website Facts and Statistics https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures [Accessed 18th October 2021]
- IOF. (n.d.) About Osteoporosis: Risk Factors. Available from: https://www.osteoporosis.foundation/patients/about-osteoporosis/risk-factors [Accessed 18th October 2021]
- Johnell, O. et al. (2004) Osteoporos Int 15 (1), 38-42.
- Nevitt, M.C. et al. (1998) Ann Intern Med 128 (10), 793-800.
- Lips, P. et al (1999) Osteoporos Int 10, 150-160.
- Tosteson, A.N. et al (2001) Osteoporos Int 12:1042-1049.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005894/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Completes Acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting Business1.12.2025 08:00:00 CET | Press release
The deal strengthens Regnology’s leadership in compliance technology, expands capabilities in risk and finance, and reinforces its commitment to innovation and client continuity. Regnology, a global leader in regulatory reporting and supervisory technology, today announces the successful closing of its acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting (FRR) business. This milestone reinforces Regnology’s position as the trusted partner for financial institutions and regulators worldwide, delivering smarter, faster compliance solutions at scale. Regnology is committed to ensuring business continuity for all FRR clients. With a proven track record in seamless migrations and a unified data model on a scalable SaaS platform, institutions can maintain compliance securely and efficiently throughout the integration process. The acquisition underscores Regnology’s vision to combine regulatory expertise with innovation. The recently launched RRH Ascend platform exemplifies th
Ant International Upgrades Antom Copilot to Advance Domain-Specific Agentic AI to Solve Global Payment Complexity1.12.2025 07:21:00 CET | Press release
Antom, a leading merchant payment and digitisation services provider under Ant International, today announced major upgrades to Antom Copilot, its industry-first AI agent designed for merchant payment and operations management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251130027598/en/ Antom Copilot supports a wide range of merchant payment operations and responds to early signs of issues with tailored recommendations. Integrated into the Antom Merchant Portal, Antom Copilot now provides enhanced automation and tailored assistance based on learnings from real-world cases, to help merchants handle payment complexity more efficiently. Main features include: Agentic support for entire payment lifecycle, from onboarding and integration, to dispute handling, risk control and payment success rate operation; Domain-trained intelligence functions like a virtual team of payment experts to manage traditionally resource-intensive
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe1.12.2025 07:00:00 CET | Press release
OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial) become available across Europe as of December 2025 and January 2026, respectivelyMarks Samsung Bioepis’ 10th and 11th biosimilars launched in Europe and second and third product to be commercialized directly by Samsung BioepisLaunch reinforces Samsung Bioepis’ biosimilar leadership in Europe as it expands its portfolio into endocrinology and builds on its growing direct sales efforts Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major challenge in Europe due to limited treatment options and affordability challenges. And bone-related events resulting from bone metastases significantly impact a pa
UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs28.11.2025 22:31:00 CET | Press release
The world’s first assessment to assess AI models’ alignment with Emirati identity and values The UAE’s Artificial Intelligence, Digital Economy, and Remote Work Applications Office announced that Google Gemini has ranked first in the “AI in the Ring” Index, the world’s first benchmark designed to evaluate how effectively AI language models reflect Emirati culture, dialects, traditions, and national values through a challenge centered on cultural intelligence within the UAE context. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251128785463/en/ UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs (Photo: AETOSWire) Gemini earned the top ranking following a review of over 400 questions across 7 cultural dimensions and 5,200 generated responses from 11 major language models. A Committee of Emirati experts evaluated the outputs to identify which models demonstrated the strongest cultural understanding. F
GE HealthCare announces CE Mark for the Omni 128cm total body PET/CT system28.11.2025 12:00:00 CET | Press release
FOR USE IN CE-MARK EUROPEAN COUNTRIES ONLY GE HealthCare announces CE Mark for its Omni 128cm total body PET/CT,i a next-generation imaging system designed to advance precision care as well as cancer diagnosis, staging and treatment planning The new system is designed to accommodate head-to-thigh imaging in a single bed to improve workflow and efficiency, and enable a significant reduction in dose/scan time – all important factors, especially for populations like pediatric patients Built for both clinical and research excellence, the system may support the development and evaluation of new clinical pathways, novel PET tracers and emerging theranostic agents GE HealthCare today announced CE Mark for its next-generation Omni 128cm total body positron emission tomography / computed tomography (PET/CT) system,i a major milestone in its mission to advance precision care. Designed to advance cancer diagnosis, staging, therapeutic planning and treatment response monitoring, this innovative sy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
